Identifying and Managing MASH Patients at Risk for Fibrosis

Panelists discuss how to identify patients most likely to progress from MASH to fibrosis using noninvasive diagnostic tools. They highlight fibrosis scoring systems, elastography, and biochemical markers as key to stratifying risk without biopsy reliance.

They emphasize that integrating these assessments into obesity and diabetes management allows for timely intervention before irreversible damage occurs. This approach also supports coverage and policy decisions that prioritize preventive care.

Panelists conclude that expanding access to advanced screening technologies within clinical practice and employer wellness programs can meaningfully reduce disease progression rates.